HeartBeam, Inc.

BEAT

$0.43

-4.22%

2026-09-03 12:54:25 EDT-$0.02

Healthcare

Medical - Specialties

NASDAQ

Active Trading

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac ...

Price Action of BEAT

$0.43

-4.22%-$0.02

High—

Low—

52W High-89.2%

Rel. vol—

Interval

Range3.8h

Volume—SMA5SMA10

—

HeartBeam, Inc. (NASDAQ: BEAT), headquartered in Santa Clara, CA, is a pioneering medical technology company dedicated to transforming cardiac care through innovative telemedicine solutions. Founded in 2015 by Branislav Vajdic, Ph.D., a seasoned technology executive with over 30 years of experience, the company develops advanced electrocardiogram (ECG) technology that allows ...HeartBeam, Inc. (NASDAQ: BEAT), headquartered in Santa Clara, CA, is a pioneering medical technology company dedicated to transforming cardiac care through innovative telemedicine solutions. Founded in 2015 by Branislav Vajdic, Ph.D., a seasoned technology executive with over 30 years of experience, the company develops advanced electrocardiogram (ECG) technology that allows for the detection and monitoring of critical cardiac conditions outside traditional medical settings. The company's flagship product is a cable-free, FDA-cleared ECG collection device that transmits cardiac signals via a smartphone to a cloud-based software expert system, enabling physicians to access diagnostic information remotely—a significant advancement in preventive cardiology and emergency care. HeartBeam operates in the Healthcare sector, specifically within the Medical - Equipment & Services industry. As a development stage company, it has not yet generated revenue, focusing instead on research and development, clinical validation, and regulatory approvals. The company's primary product aims to address the limitations of traditional ECG monitoring by providing a user-friendly, portable solution that empowers patients to record cardiac events and transmit data in real time. This technology is particularly valuable for detecting arrhythmias and other cardiac abnormalities, potentially reducing hospital visits and improving patient outcomes. Financially, HeartBeam is in a pre-revenue phase, with no gross profit margins. As of the latest data, it has a market capitalization of approximately $31.7 million, with a low beta of -0.793, indicating low volatility relative to the market. The company's financial metrics show negative returns on assets and equity, reflecting its development stage and investment in research. Key financial indicators include a negative enterprise value-to-sales ratio, high negative return on equity (-10.34), and negative free cash flow, all typical for a company investing heavily in product development and regulatory efforts. With only 16 full-time employees, HeartBeam operates with a lean team, relying on strategic partnerships and licensing opportunities. Leadership is a critical asset: Robert Eno was appointed CEO in October 2024, bringing extensive experience in medical technology commercialization. Founder Branislav Vajdic serves as President, steering the company's vision and technological direction. The company plans to initiate a limited launch in early 2026, targeting concierge and preventive cardiology groups, with a potential strategic shift toward a licensing model to accelerate adoption. HeartBeam's focus on remote cardiac monitoring positions it to capitalize on the growing telehealth market, and its recent FDA clearance is a pivotal milestone. With a dedicated team and innovative product, HeartBeam aims to establish itself as a key player in cardiovascular diagnostics, improving patient care and reducing healthcare costs.ExpandCollapse

Founded

2015

Employees

CEO

Branislav Vajdic

Full Name

HeartBeam, Inc.

Sector

Healthcare

Industry

Medical - Specialties

ROE

-686.78%

Market Cap

$0.02B

Current Ratio

3.66

WACC

5.48%

ROIC

-250.60%

Contact Information

https://www.heartbeam.com

408 899 4443

2118 Walsh Avenue, Santa Clara, CA 95050

Key Metrics of BEAT

Snapshot

Latest / TTM · 6 periods

Market Cap

$23.93M

ROCE

-249.6%

EV / EBITDA

-0.75x

+562.5% YoY

FCF Yield

-58.6%

-40.5% YoY

Cash Conversion Cycle

-7573.8d

Current Ratio

3.66

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of BEAT

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-0.83x

n/a

Debt / Equity

0.00

n/a

Current Ratio

3.66

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of BEAT

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.09 · Revenue $112500.00 · 3 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.06 · Revenue $300000.00 · 3 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.39 · Revenue $412500.00 · 2 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.08 · Revenue $400000.00 · 1 analysts

Recent history

Aug 13, 2026
Q2 FY2026 · Results reported
EPS $-0.10 · Revenue $0.00
View filing
May 13, 2026
Q1 FY2026 · Results reported
EPS $-0.12 · Revenue $0.00
View filing
Mar 12, 2026
FY2025 · Annual results
EPS $-0.62 · Revenue $0.00
View filing
Nov 13, 2025
Q3 FY2025 · Results reported
EPS $-0.15 · Revenue $0.00
View filing
Aug 13, 2025
Q2 FY2025 · Results reported
EPS $-0.15 · Revenue $0.00
View filing
May 13, 2025
Q1 FY2025 · Results reported
EPS $-0.18 · Revenue $0.00
View filing

Financial Statements of BEAT

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-21.0M	-8.1%	-7.2%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-14.6M	+0.6%	+6.9%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	0.0%	—	—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	1.45x	-15.3%	+394.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$5.8M	+78.4%	+170.7%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.62 vs -0.61	-1.2%	-0.10 vs -0.09	-11.1%
Revenue Surprise	$0 vs $2.1M	-100.0%	$0 vs $112500	-100.0%

Insider Transactions of BEAT

Acquisitions (A)

Since Apr 16, 2026

Disposals (D)

Since Apr 16, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jul 24, 2026	Persen Kenneth Harry	officer: Chief Technology Officer	Common Stock	A	105,740	—
Jul 24, 2026	Cruickshank Tim	officer: CFO	Common Stock	A	167,760	—
Jul 24, 2026	Vajdic Branislav	director, officer: President	Common Stock	A	260,870	—
Jun 15, 2026	Vajdic Branislav	director, officer: President	Common Stock	A	2,800,000	—
Apr 16, 2026	Ferrari Richard	director	Common Stock	A	57,500	$0.80

Earnings Call Transcript of BEAT

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Greetings, and welcome to the HeartBeam second quarter 2026 financial results conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference call is being recorded. Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates, or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions. You should also review our most recent Form 10-K and Form 10-Q for a more complete discussion of these factors and other risks, particularly under the heading Risk Factors. A press release detailing these results crossed the wire this afternoon and is available in the investor relations section of our company's website, heartbeam.com. Your hosts today, Richard Ferrari, Executive Chairman, Branislav Vajdic, Founder and President, and Tim Cruickshank, Chief Financial Officer, will present results of operations for the second quarter ended June 30, 2026. At this time, I'll turn the call over to HeartBeam Executive Chairman, Mr. Richard Ferrari. Richard Ferrari: Good afternoon, everyone, and thank you for taking the time. I know your schedules are very busy. We have a nice tight presentation to provide for you and the agenda, as you can see. I will walk through those elements, the core technology, our highlights, heart attack detection, our initial commercial launch, and the financials. If we go to the next slide. Are we on the next, we're on the next slide? Operator: Yeah, we are. Richard Ferrari: Yeah, just if you could, because I can't see whether or not we've moved to the next slide. Just let me know that, okay, that slide is up. As you can see from this slide, this to me really frames what really gets all of us at HeartBeam incredibly excited is the fact that every 40 seconds someone suffers from a heart attack. Our technology, which is utilizing TriCor signal capturing technology, is the only true way to evaluate the real extent of that trauma. To reach as many of these patients as possible, we've developed and tested three different form factors, each with a unique approach. As you already know, the card fits into the post-discharge space where many patients, we feel, will find …

Leadership Team of BEAT

9 executives

Name	Title	Compensation	Gender	Year Born	Status
Branislav Vajdic	Founder, President & Director	USD 615,135	—	1955	Active
Robert Eno	CEO & Chief Business Officer	USD 544,628	Male	1968	Active
Timothy Cruickshank	Chief Financial Officer	USD 479,274	Male	1982	Active
Kenneth Persen	Chief System Development Officer	USD 398,586	Male	—	Active
Richard Ferrari	Executive Chairman	USD 72,500	Male	1954	Active
Richa Gujarati	Senior Vice President of Product	—	Female	—	Active
Lance Myers	Chief Artificial Intelligence Scientist	—	—	—	Active
Peter J. Fitzgerald FACC	Member of Scientific Advisory Board & Chief Medical Advisor	—	—	1957	Active
Bryan Humbarger	Chief Commercial Officer	—	Male	—	Active

Recent News of BEAT

Seeking Alpha8/14/2026Neutral

HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript

Business Wire8/13/2026Neutral

HeartBeam Reports Second Quarter 2026 Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Second Quarter 2026 Results.

Business Wire7/30/2026Neutral

HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time.

Zacks Investment Research7/16/2026Neutral

Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now

Healthcare IT is emerging as AI's next growth story as providers adopt AI to cut costs & improve care. Here we present three stocks that are likely to benefit.

GuruFocus7/14/2026Neutral

HeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG Device

[url="]HeartBeam, Inc.[/url] (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today an

Historical Employee Count of BEAT

Current

Change

-23.81%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	16	10-K	Mar 12, 2026	View
Dec 31, 2024	21	10-K	Mar 13, 2025	View
Dec 31, 2023	15	10-K	Mar 20, 2024	View
Dec 31, 2022	15	10-K	Mar 16, 2023	View
Dec 31, 2021	5	10-K	Mar 24, 2022	View

Related stocksMedical - Equipment & Services

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

HeartBeam, Inc.